TipRanks
GlaxoSmithKline (MX:GSK1N)
:GSK1N
Mexico Market
GSK1N
GlaxoSmithKline
RESEARCH TOOLSreports

GlaxoSmithKline (GSK1N) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

GSK1N Analyst Ratings

Hold
14Ratings
Hold
3 Buy
8 Hold
3 Sell
Based on 14 analysts giving stock ratings to
GlaxoSmithKline
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GSK1N Stock 12 Month Forecast

Average Price Target

$518.02
▲(21.52% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for GlaxoSmithKline in the last 3 months. The average price target is $518.02 with a high forecast of $741.53 and a low forecast of $418.80. The average price target represents a 21.52% change from the last price of $426.27.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"323":"$323","742":"$742","427.75":"$427.8","532.5":"$532.5","637.25":"$637.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":741.525423814,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$741.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":518.01810645,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$518.02</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":418.80173438,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$418.80</span>\n  </div></div>","useHTML":true}}],"tickPositions":[323,427.75,532.5,637.25,742],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,426.27,450.5204172164615,474.77083443292304,499.02125164938457,523.2716688658461,547.5220860823076,571.7725032987692,596.0229205152307,620.2733377316922,644.5237549481537,668.7741721646153,693.0245893810768,717.2750065975384,{"y":741.525423814,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,426.27,433.32754665,440.3850933,447.44263995,454.5001866,461.55773325,468.6152799,475.67282654999997,482.7303732,489.78791985,496.8454665,503.90301315,510.9605598,{"y":518.01810645,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,426.27,425.69551802923075,425.1210360584615,424.5465540876923,423.9720721169231,423.39759014615385,422.8231081753846,422.2486262046154,421.67414423384616,421.09966226307694,420.5251802923077,419.9506983215385,419.37621635076925,{"y":418.80173438,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":324.376,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":324.376,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":328.1,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":328.1,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":328.1,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":332.183,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 20</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":332.183,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 21</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":332.183,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":336.083,"date":1780272000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":336.083,"date":1782864000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":336.083,"date":1785542400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 19</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":426.27,"date":1788220800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 19</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":426.27,"date":1790812800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$741.53Average Price Target$518.02Lowest Price Target$418.80
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on MX:GSK1N
Zain Ebrahim
J.P. Morgan
J.P. Morgan
$418.8
Sell
-1.75%
Downside
Reiterated
10/21/26
GlaxoSmithKline (GSK) Receives a Sell from J.P. Morgan
Barclays Analyst forecast on MX:GSK1N
James Gordon CFA
Barclays
Barclays
$443.44
Sell
4.03%
Upside
Reiterated
10/20/26
Barclays Sticks to Its Sell Rating for GlaxoSmithKline (GSK)
RBC Capital Analyst forecast on MX:GSK1N
Trung Huynh
RBC Capital
RBC Capital
$486.58
Hold
14.15%
Upside
Reiterated
10/19/26
RBC Capital Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
Jefferies Analyst forecast on MX:GSK1N
Michael Leuchten
Jefferies
Jefferies
$615.88
Buy
44.48%
Upside
Reiterated
10/19/26
Jefferies Reaffirms Their Buy Rating on GlaxoSmithKline (GSK)
UBS Analyst forecast on MX:GSK1N
Matthew Weston
UBS
UBS
$477.93
Hold
12.12%
Upside
Reiterated
10/15/26
UBS Keeps Their Hold Rating on GlaxoSmithKline (GSK)
Berenberg Bank Analyst forecast on MX:GSK1N
Kerry Holford
Berenberg Bank
Berenberg Bank
$541.98
Buy
27.14%
Upside
Reiterated
10/14/26
GlaxoSmithKline (GSK) Receives a Buy from Berenberg Bank
Goldman Sachs Analyst forecast on MX:GSK1N
Rajan Sharma
Goldman Sachs
Goldman Sachs
$468.1→$458.25
Hold
7.50%
Upside
Reiterated
10/05/26
Goldman Sachs Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)
Deutsche Bank Analyst forecast on MX:GSK1N
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
$492.71
Hold
15.59%
Upside
Reiterated
09/29/26
Deutsche Bank Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)
Citi Analyst forecast on MX:GSK1N
Graham Parry
Citi
Citi
$517.34
Hold
21.37%
Upside
Reiterated
09/15/26
GlaxoSmithKline (GSK) Receives a Hold from Citi
HSBC Analyst forecast on MX:GSK1N
Rajesh Kumar
HSBC
HSBC
$458.25→$492.74
Hold
15.59%
Upside
Reiterated
09/10/26
GSK price target raised to 2,000 GBp from 1,860 GBp at HSBCGSK price target raised to 2,000 GBp from 1,860 GBp at HSBC
Bank of America Securities Analyst forecast on MX:GSK1N
Sachin Jain
Bank of America Securities
Bank of America Securities
$578.97
Hold
35.82%
Upside
Reiterated
09/04/26
GSK: Pipeline Optionality Recognized but Near-Term Data Gaps Keep Rating at Hold and Price Target Unchanged at 2,350 GBp
Morgan Stanley Analyst forecast on MX:GSK1N
Sarita Kapila
Morgan Stanley
Morgan Stanley
$431.15→$468.1
Sell
9.81%
Upside
Reiterated
08/25/26
Morgan Stanley Keeps Their Sell Rating on GlaxoSmithKline (GSK)
Bernstein Analyst forecast on MX:GSK1N
Justin Smith
Bernstein
Bernstein
$695.95→$741.53
Buy
73.96%
Upside
Reiterated
08/03/26
Bernstein Sticks to Their Buy Rating for GlaxoSmithKline (GSK)
DZ BANK AG Analyst forecast on MX:GSK1N
Elmar Kraus
DZ BANK AG
DZ BANK AG
―
Hold
―
Reiterated
07/29/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Crispr Therapeutics AG (NASDAQ: CRSP) and GlaxoSmithKline (LSE: GB:GSK)
Guggenheim Analyst forecast on MX:GSK1N
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
07/09/26
Guggenheim Remains a Hold on GlaxoSmithKline (GSK)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on MX:GSK1N
Zain Ebrahim
J.P. Morgan
J.P. Morgan
$418.8
Sell
-1.75%
Downside
Reiterated
10/21/26
GlaxoSmithKline (GSK) Receives a Sell from J.P. Morgan
Barclays Analyst forecast on MX:GSK1N
James Gordon CFA
Barclays
Barclays
$443.44
Sell
4.03%
Upside
Reiterated
10/20/26
Barclays Sticks to Its Sell Rating for GlaxoSmithKline (GSK)
RBC Capital Analyst forecast on MX:GSK1N
Trung Huynh
RBC Capital
RBC Capital
$486.58
Hold
14.15%
Upside
Reiterated
10/19/26
RBC Capital Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
Jefferies Analyst forecast on MX:GSK1N
Michael Leuchten
Jefferies
Jefferies
$615.88
Buy
44.48%
Upside
Reiterated
10/19/26
Jefferies Reaffirms Their Buy Rating on GlaxoSmithKline (GSK)
UBS Analyst forecast on MX:GSK1N
Matthew Weston
UBS
UBS
$477.93
Hold
12.12%
Upside
Reiterated
10/15/26
UBS Keeps Their Hold Rating on GlaxoSmithKline (GSK)
Berenberg Bank Analyst forecast on MX:GSK1N
Kerry Holford
Berenberg Bank
Berenberg Bank
$541.98
Buy
27.14%
Upside
Reiterated
10/14/26
GlaxoSmithKline (GSK) Receives a Buy from Berenberg Bank
Goldman Sachs Analyst forecast on MX:GSK1N
Rajan Sharma
Goldman Sachs
Goldman Sachs
$468.1→$458.25
Hold
7.50%
Upside
Reiterated
10/05/26
Goldman Sachs Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)
Deutsche Bank Analyst forecast on MX:GSK1N
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
$492.71
Hold
15.59%
Upside
Reiterated
09/29/26
Deutsche Bank Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)
Citi Analyst forecast on MX:GSK1N
Graham Parry
Citi
Citi
$517.34
Hold
21.37%
Upside
Reiterated
09/15/26
GlaxoSmithKline (GSK) Receives a Hold from Citi
HSBC Analyst forecast on MX:GSK1N
Rajesh Kumar
HSBC
HSBC
$458.25→$492.74
Hold
15.59%
Upside
Reiterated
09/10/26
GSK price target raised to 2,000 GBp from 1,860 GBp at HSBCGSK price target raised to 2,000 GBp from 1,860 GBp at HSBC
Bank of America Securities Analyst forecast on MX:GSK1N
Sachin Jain
Bank of America Securities
Bank of America Securities
$578.97
Hold
35.82%
Upside
Reiterated
09/04/26
GSK: Pipeline Optionality Recognized but Near-Term Data Gaps Keep Rating at Hold and Price Target Unchanged at 2,350 GBp
Morgan Stanley Analyst forecast on MX:GSK1N
Sarita Kapila
Morgan Stanley
Morgan Stanley
$431.15→$468.1
Sell
9.81%
Upside
Reiterated
08/25/26
Morgan Stanley Keeps Their Sell Rating on GlaxoSmithKline (GSK)
Bernstein Analyst forecast on MX:GSK1N
Justin Smith
Bernstein
Bernstein
$695.95→$741.53
Buy
73.96%
Upside
Reiterated
08/03/26
Bernstein Sticks to Their Buy Rating for GlaxoSmithKline (GSK)
DZ BANK AG Analyst forecast on MX:GSK1N
Elmar Kraus
DZ BANK AG
DZ BANK AG
―
Hold
―
Reiterated
07/29/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Crispr Therapeutics AG (NASDAQ: CRSP) and GlaxoSmithKline (LSE: GB:GSK)
Guggenheim Analyst forecast on MX:GSK1N
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
07/09/26
Guggenheim Remains a Hold on GlaxoSmithKline (GSK)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PTGXProtagonist Therapeutics
SIBNSI-Bone
IMUXImmunic
MDWDMediwound
HROWHarrow Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering GlaxoSmithKline

3 Months
Kerry HolfordBerenberg Bank
Success Rate
19/34 ratings generated profit
56%
Average Return
+0.95%
Copying Kerry Holford's trades and holding each position for 3 Months would result in 55.88% of your transactions generating a profit, with an average return of +0.95% per trade.
1 Year
Michael LeuchtenJefferies
Success Rate
21/33 ratings generated profit
64%
Average Return
+4.29%
Copying Michael Leuchten's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +4.29% per trade.
2 Years
Justin SmithBernstein
Success Rate
13/22 ratings generated profit
59%
Average Return
+9.13%
Copying Justin Smith's trades and holding each position for 2 Years would result in 59.09% of your transactions generating a profit, with an average return of +9.13% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GSK1N Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
0
1
1
1
Buy
8
9
7
6
6
Hold
25
28
25
27
19
Sell
16
16
19
19
18
Strong Sell
0
0
0
0
0
total
49
53
52
53
44
In the current month, GSK1N has received 7 Buy Ratings, 19 Hold Ratings, and 18 Sell Ratings. GSK1N average Analyst price target in the past 3 months is 518.02.
Each month's total comprises the sum of three months' worth of ratings.

GSK1N Financial Forecast

GSK1N Earnings Forecast

Next quarter’s earnings estimate for GSK1N is $12.62 with a range of $10.99 to $13.19. The previous quarter’s EPS was $12.67. GSK1N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year GSK1N has Performed in-line its overall industry.
Next quarter’s earnings estimate for GSK1N is $12.62 with a range of $10.99 to $13.19. The previous quarter’s EPS was $12.67. GSK1N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year GSK1N has Performed in-line its overall industry.

GSK1N Sales Forecast

Next quarter’s sales forecast for GSK1N is $222.10B with a range of $218.37B to $228.64B. The previous quarter’s sales results were $210.91B. GSK1N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year GSK1N has Performed in-line its overall industry.
Next quarter’s sales forecast for GSK1N is $222.10B with a range of $218.37B to $228.64B. The previous quarter’s sales results were $210.91B. GSK1N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year GSK1N has Performed in-line its overall industry.

GSK1N Stock Forecast FAQ

What is MX:GSK1N’s average 12-month price target, according to analysts?
Based on analyst ratings, GlaxoSmithKline’s 12-month average price target is 518.02.
    What is MX:GSK1N’s upside potential, based on the analysts’ average price target?
    GlaxoSmithKline has 21.52% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is GlaxoSmithKline a Buy, Sell or Hold?
          GlaxoSmithKline has a consensus rating of Hold, which is based on 3 buy ratings, 8 hold ratings and 3 sell ratings.
            What is GlaxoSmithKline’s share price target?
            The average share price target for GlaxoSmithKline is 518.02. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $741.53 ,and the lowest forecast is $418.80. The average share price target represents 21.52% Increase from the current price of $426.27.
              What do analysts say about GlaxoSmithKline?
              GlaxoSmithKline’s analyst rating consensus is a Hold. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of GlaxoSmithKline?
                To buy shares of MX:GSK1N, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.